



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/713,929	11/14/2003	Gopi Venkatesh	EUR-004/00US 307853-2001	4820
58249 7590 01/11/2008 COOLEY GODWARD KRONISH LLP ATTN: Patent Group Suite 1100 777 - 6th Street, NW WASHINGTON, DC 20001			EXAMINER BARHAM, BETHANY P	
			ART UNIT 1615	PAPER NUMBER
			MAIL DATE 01/11/2008	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/713,929	Applicant(s) VENKATESH ET AL.	
	Examiner Bethany P. Barham	Art Unit 1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 October 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-11 and 24-40 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-11 and 24-40 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/ are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>01/03/08</u> | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicant's IDS filed on 01/03/08 and Applicant's Response and Amended Claims filed on 10/22/07 are acknowledged. The previous rejections of record (08/27/07) are hereby **withdrawn**. Claims 1-11 and 24-40 are pending. Claims 1-11 and 24-40 are rejected.

OBJECTIONS

The amendment filed 10/22/07 is objected to under 35 U.S.C. 132(a) because it introduces new matter into the disclosure. 35 U.S.C. 132(a) states that no amendment shall introduce new matter into the disclosure of the invention. The added material which is not supported by the original disclosure is as follows: amendment to claim 1 and specification:

"Examples of appropriate polymers for coating applications include cellulose esters and ethers such as cellulose acetate, cellulose butyrates, cellulose propionate, ethylcellulose, and mixed cellulose esters, acylated polysaccharides, polyurethanes, polyacrylate and polymethylacrylate polymers and derivatives. Preferred coating thicknesses range from about 1 to about 1000 microns, most preferably between about 20 to about 500 microns. Waxes may also be used to coat the product."

Applicant is required to cancel the new matter in the reply to this Office Action. Applicant cannot pick and choose portions of the prior art incorporated to add to the disclosure.

NEW REJECTIONS:

Claim Rejections – 35 USC §112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-11 and 24-40 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicant has submitted an amendment to claim 1 and the specification (10/22/07), which incorporates new matter. This is a new matter rejection.

Claims 1-11 and 24-40 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The instant claim 1 is directed to a multi-particulate dosage form comprising "wherein said extended release beads comprise an active-containing core particle...of cyclobenzaprine; an extended release

coating comprising a water insoluble polymer membrane surrounding said core" and further a functional limitation of a specific dissolution profile:

USP Apparatus 2 (paddles @ 50 rpm) in 900 mL of 0.1N HCl at 37°C exhibits a drug release profile substantially corresponding to the following pattern:
after 2 hours, no more than about 40% of the total active is released;
after 4 hours, from about 40-65% of the total active is released;
and after 8 hours, from about 60-85% of the total active is released;
wherein said dosage form provides therapeutically effective plasma concentration over a period of 24 hours to treat muscle spasm associated with painful musculoskeletal conditions when administered to a patient in need thereof.

The claims contain no actual structure, but are only defined by functional limitations such as drug dissolution profiles and AUC, etc.

Claim Rejections – 35 USC §103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-11 and 24-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 2004/0197407 A1 ('407) in view of Patel et al US 2003/0215496 A1.

'407 teach the limitations of claims 1-7, and 24-25:

- '407 teaches a sustained release dosage form of cyclobenzaprine for administration once a day, with optimal ascending release rate and consistent performance (abstract, claim 1).
- '407 teaches that a sustained or controlled formulation for cyclobenzaprine can be made and overcomes previous side effects due to high drug loading, etc, that tolerance is increased, and a delivery profile provides 24 hours of efficacy [0006-0010, 0023]. '407 also teaches that various sustained release formulations are known such as osmotic, reservoir devices, matrix devices, dissolution systems such as encapsulated dissolution systems ('tiny time pills'), combination diffusion/dissolution systems, etc and that a delayed release coating such as an enteric coating may be employed to ensure 85% or more of the drug releases in the large intestine which can take up to and over 6 hours to release [0009, 0011].
- '407 teaches dosage forms with cyclobenzaprine hydrochloride [0023] and Examples.
- '407 does not specifically teach a multi-particulate matrix bead formulation, but does teach extended release coatings on a core and that matrix formulations are known.

- Patel et al teaches compositions that can be provided in the form of a minicapsule, a capsule, tablet,....a pellet, a bead, etc ([0168] and claims 5-7, 52). Examples 1-5 teaches how to prepare active ingredient coated beads. Patel et al teaches a composition comprising muscle skeletal relaxants and cyclobenzaprine, salts, isomers and derivatives and mixtures thereof ([0036] and claim 24).
- Pharmaceutical composition and/or the solid carrier particles taught by Patel et al can be coated with one or more enteric coatings, seal coatings, film coatings, barrier coatings, etc., and that the dosage form can be designed for immediate release, pulsatile release, controlled release, extended release, delayed release, targeted release, synchronized release, or targeted delayed release ([0169, col. 1] and claims 1, 53, and 59-60). Patel et al also teaches that the dosage form release profile can be affected by a polymeric matrix composition, a coated matrix composition, a multiparticulate composition, a coated multiparticulate composition, etc [0169, col. 2].

The limitations of claims 8-9, 27-29 and 36-38 are taught:

- The extended release coatings of Patel et al are preferably pH-independent coatings formed of, for example, ethyl cellulose [0172] and delayed release enteric coatings are acrylic polymers methacrylic acid copolymers, ammonio methacrylate copolymers, the Eudragit series E, L, S, RL, RS, NE and L-30D, and ethyl cellulose ([0184-0185], Example 8).

- Patel et al teaches that the coating can and usually does contain a plasticizer such as: triethyl citrate triacetin, acetyl triethyl citrate, polyethylene glycol 400, diethyl phthalate, tributyl citrate, acetylated monoglycerides, glycerol, fatty acid esters, propylene glycol and dibutyl phthalate [0189].

The limitations of claim 10-11, 26, 30-35 and 39-40 are taught:

- Patel et al teaches that various extended release dosage forms can be readily designed by one skilled in the art to achieve delivery to both the small and large intestines, to only the small intestine or to only the large intestine, depending on the choice of coating materials and/or coating thickness [0172].
- Extended release coatings of Patel et al also teach water soluble polymers such as hydroxypropyl cellulose, methylcellulose, hydroxymethyl cellulose, acrylic esters, etc. [0172].
- Patel et al does not teach the specific drug release profiles and concentrations as claimed by applicant, but teaches the same coatings, coating thickness and drug as instant claimed and that one of ordinary skill in the art would know how to obtain a dosage with a desired performance, specifically extended release ([0169, 0172] claims 59-60).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to look to Patel et al to make an extended release matrix dosage form of cyclobenzaprine or cyclobenzaprine HCl as taught by '407. '407 teaches a need for sustained release of cyclobenzaprine in order to decrease side effects, increase efficacy and tolerance; and that matrix formulations and delayed release enteric coating are

known. Patel et al teaches various drugs including cyclobenzaprine coated enterically onto beads for extended release. One of ordinary skill in the art would be motivated to combine '407 and Patel in order to decrease side effects, increase tolerance and efficacy and further Patel et al teaches that obtaining specific release profiles and dissolution are within the knowledge of one of ordinary skill in the art and that they would how to vary the coatings and dosage form to obtain a desired performance.

Claims 1-4, 6-11 and 24-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 2004/0197407 A1 ('407) in view of Meadows et al US 2003/0099711 A1.

'407 in view of Meadows et al teaches the limitations of claim 1-4, 6-7 and 24-25:

- '407 is taught above and teaches sustained release dosage forms with cyclobenzaprine hydrochloride [0023] and Examples (abstract, claim 1).
- '407 does not teach specifically teach a multi-particulate matrix bead formulation, but does teach extended release coatings on a core and that matrix formulations are known.
- Meadows et al teaches that the composition of their invention can be coated with a water-permeable diffusion barrier coating that is insoluble in gastrointestinal fluids thereby providing a controllable sustained release of drug and/or an enteric coating to formulate tailored release profiles [0001, 0009-0010, 0023]. Meadows et al teaches that the invention provides therapeutic levels of the drug throughout

the day and a controlled release drug preparation delivers drugs in a manner that will maintain therapeutically effective plasma levels over a period of time that is significantly longer than that which is given by a typical drug dosage form [0002].

- Meadows et al teaches that cyclobenzaprine is a suitable drug for their composition ([0029], col. 2 and claim 13).

The limitation of claims 27 is taught:

- Meadows et al teaches coating with a diffusion barrier, preferably ethyl cellulose, such as Aquacoat or Surelease [0040, 0042-0043] and/or enteric coatings to allow the active ingredients to be released once the dosage has passed into the small intestinal tract [0046]. The enteric coating include copolymers of methacrylic acid and methyl methacrylate or ethyl acrylate, terpolymers of methacrylic acid, methacrylate, and ethyl acrylate [0047].
- Meadows et al teach that it is possible to tailor the drug release properties of the pharmaceutical preparation to provide a desired bioavailability profile, such as enteric coated free drug adsorbed on an inert substrate [0062-0067]. Meadows et al found that the enteric coated particles provide release in vivo of at least one drug over a period of about 4 hours, preferably over a period of 12 hours and more preferably the formulations of the present invention release in vivo at least one drug over a period of 24 hours ([0070] and claims 1, 8, 30 and 37-39).

The limitations of claim 8-9, 27-29 and 36-38 are taught:

- Plasticizers are generally used for coating containing film-formers such as ethyl cellulose [0040]. Examples of suitable plasticizers for ethyl cellulose are dibutyl

sebacate, diethyl phthalate, triethyl citrate, tributyl citrate, triacetin, acetylated monoglycerides, phthalate esters, castor oil, etc. [0041].

Meadows et al teaches the limitations of claims 10-11, 26, 30-35 and 39-40 are taught:

- The optimum coat weight and thickness for barrier coating materials is taught by Meadows et al to be determined specifically for each drug-resin complex. For drug release from about 1-4 hours the coat weight is present in amount of about 10-20% by weight of the dry resin. For drug release from about 6-10 hours the coat weight is present in amount of about 30-35% by weight of the dry resin, etc. [0044]. Meadows et al teaches that the water-permeable, film-forming polymer comprises from about 1 to about 60% by weight of the drug-resin complex (claim 1). For the enteric coating (claim 14) taught by Meadows et al it may be desirable to provide the coating directly onto the drug-resin complex or on a drug adsorbed on an inert substrate such as sugar spheres in the amounts of about 1.5- about 30%, preferably about 5- about 15% by weight of the particle being coated [0048].
- Water-soluble substances are taught by Meadows et al as desirable to incorporate into the coating in order to alter permeability [0041]. Such substances are HPMC, HEC, methylcellulose or other cellulose polymers or mixtures of polymers [0040].
- Meadows et al does not teach the specific drug release profiles and concentrations as claimed by applicant, but teaches the same coatings, coating thickness and drug as instant claimed and that one of ordinary skill in the art

would obtain dosage form with a tailored release profile (abstract) to provide a desired bioavailability and drug release for over a period of 24 hours ([0062, 0070] claims 8 and 39).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to look to Meadows et al to make an extended release matrix dosage form of cyclobenzaprine or cyclobenzaprine HCl as taught by '407. '407 teaches a need for sustained release of cyclobenzaprine in order to decrease side effects, increase efficacy and tolerance; and that matrix formulations and delayed release enteric coating are known. Meadows et al teaches various drugs including cyclobenzaprine coated enterically onto beads for controlled release in vivo of a drug for over a period of 24 hours. Meadows et al teaches in their examples (example 5) that dissolution of the formulations of the invention can be formulated to selectively release a specific amount of drug. One of ordinary skill in the art would be motivated to combine '407 and Meadows et al in order to decrease side effects, increase tolerance and efficacy and further Meadows et al teaches that obtaining specific release profiles and dissolution are within the knowledge of one of ordinary skill in the art and that they would how to vary the coatings and dosage form to obtain a desired performance.

Response to Arguments

Applicant's arguments with respect to claims 1-11 and 24-40 have been considered but are moot in view of the new grounds of rejection necessitated by applicants' amendments.

Under absence of showing unexpected results, the teachings of '407 in view of Patel or Meadows render the same composition as applicant's instant claimed, and the release profiles would therefore be the same.

Conclusions

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bethany P. Barham whose telephone number is 571-272-6175. The examiner can normally be reached on M-F from 8:30am to 5pm.


Application/Control Number:
10/713,929
Art Unit: 1615

Page 13

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bethany Barham
Examiner 1615


MICHAEL P. WOODWARD
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600